However, since it has been reported that platinum‐based chemotherapy and poly ADP‐ribose polymerase (PARP) inhibitors are effective for pancreatic cancer with BRCA2 genetic mutations and PALB2 genetic mutations (but not covered by insurance for pancreatic cancer), genetic testing may enable the selection of treatment based on precision medicine.18 The gene discussed is PALB2; the disease is familial pancreatic carcinoma.